A new medication has been approved for advanced pancreatic cancer. This medication is taken once daily and has shown promising results in clinical trials. It targets specific proteins that contribute to tumor growth in pancreatic cancer.

The approval is significant as it offers new hope for patients with this type of cancer. Further details about the medication and its clinical trials are available.

The medication's ability to target these proteins is a notable development, as scientists have struggled to find effective ways to do so in the past.